Research Suggests Heart Disease, Kidney Disease and Type 2 Diabetes May Be One Condition Treatable with GLP-1 Drugs
By
Brajeshwar
Crisp on the outside, thoughtful on the inside. A keeper.
Summary
The article discusses the emerging medical concept of "CKM syndrome" (cardiometabolic kidney syndrome), which suggests that heart disease, kidney disease, and type 2 diabetes may be interconnected manifestations of a single underlying condition rather than separate disorders. It presents the case study of Amy Bies, who experienced multiple health issues despite standard treatments, and explores how new GLP-1 drugs like Ozempic may offer a unified treatment approach by addressing the root metabolic dysfunction. The article examines the scientific evidence supporting this integrated view of cardiometabolic diseases and the potential paradigm shift in treatment strategies.
Key quotes
· 3 pulledAmy Bies was recovering in the hospital from injuries inflicted during a car accident in May 2007 when routine laboratory tests showed that her blood glucose and cholesterol were both dangerously high.
The combo, however, didn't prevent a heart attack in 2013. And by 2019 she was on 12 different prescriptions to manage her continued high cholesterol and her diabetes and to reduce her
These three disorders could really be 'CKM syndrome,' which can be treated with drugs like Ozempic
You might also wanna read
National Psoriasis Foundation Review Examines GLP-1 Receptor Agonists for Psoriasis with Metabolic Comorbidities
This review from the US National Psoriasis Foundation Medical Board provides an evidence-informed narrative synthesis on GLP-1 receptor agon
doi.org·5d ago
GLP-1 Prescriptions Rise as U.S. Obesity Rates Show Modest Decline, New Data Indicates
New data from EPIC Research shows that GLP-1 medications like Ozempic and Wegovy are having a population-wide impact on obesity rates. As pr
gizmodo.com·2d ago